Clomifene
 | |
| Clinical data | |
|---|---|
| Pregnancy category |
|
| Routes of administration | 50 mg tablets |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | High (>90%) |
| Metabolism | Hepatic (with enterohepatic circulation) |
| Elimination half-life | 5-7 days |
| Excretion | Mainly renal, some biliary |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C26H28ClNO |
| Molar mass | 406 or 598.10 (with citrate) |
|
WikiDoc Resources for Clomifene |
|
Articles |
|---|
|
Most recent articles on Clomifene |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Clomifene at Clinical Trials.gov Clinical Trials on Clomifene at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Clomifene
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Clomifene Discussion groups on Clomifene Directions to Hospitals Treating Clomifene Risk calculators and risk factors for Clomifene
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Clomifene |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Clomifene (INN) or clomiphene (USAN and former BAN) or Clomid or Clomifert is a selective estrogen receptor modulator (SERM), used mainly in female infertility due to anovulation (e.g. due to polycystic ovary syndrome). In some countries, it is also registered for use in men. Clomiphene citrate is marketed under various trade names including Clomid, Serophene, Milophene, etc.
Mode of action
Clomifene acts by inhibiting the action of estrogen on the gonadotrope cells in the anterior pituitary gland. In response to low estrogen levels, follicle-stimulating hormone (FSH) release is increased, leading to a higher rate of ovulation and hence pregnancy.
Clomifene can lead to multiple ovulation, and hence increasing the chance of twins. In comparison to purified FSH, the rate of ovarian hyperstimulation syndrome is low. There may be an increased risk of ovarian cancer and weight gain.
Chemistry
Clomifene is a diastereomeric mixture of two geometric isomers, enclomifene (E-clomifene) and zuclomifene (Z-clomifene).
 |
 |
Adverse effects
Common adverse drug reactions associated with the use of clomifene (≥1% of patients) include: hot flashes, abdominal discomfort, visual blurring, and/or reversible ovarian enlargement and cyst formation. Infrequent adverse effects (0.1–1% of patients) include: abnormal uterine bleeding, nausea, and/or vomiting. Rare adverse effects (<0.1% of patients) include: reversible alopecia and/or ovarian hyperstimulation syndrome.[1] In some cases, patients have developed palinopsia.[2]
Use in bodybuilding
Clomifene is commonly used by male anabolic steroid users to bind the estrogen receptors in their bodies, thereby blocking the effects of estrogen, i.e., gynecomastia. It also restores the body's natural production of testosterone. It is commonly used as a "recovery drug" and taken toward the end of a steroid cycle.
References
- ↑ Rossi S, editor. Australian Medicines Handbook 2006. Adelaide: Australian Medicines Handbook; 2006. ISBN 0-9757919-2-3
- ↑ Purvin VA (1995). "Visual disturbance secondary to clomiphene citrate". Arch Ophthalmol. 113 (4): 482–4. PMID 7710399.
External links
- Pages with script errors
- Drugs with non-standard legal status
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Citrates
- Selective estrogen receptor modulators
- Endocrinology